Barclays Keeps 'Overweight' on Alexion Pharmaceuticals (ALXN); Beat & Raise with Three Potential Catalysts Ahead
Tweet Send to a FriendGet Alerts ALXN Hot Sheet
Price: $92.39 +1.17%
Rating Summary:
10 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
10 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade ALXN Now!
Barclays maintains an 'Overweight' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $112.00 (from $104.00).
Analyst, Ying Huang calls Q2 earnings results an impressive beat and raise.
Looking forward Huang said, "Three potential catalysts on the horizon. We look forward to 1) the results of the Phase II investigator trial of Soliris in severe and refractory neuromyelitis optica (NMO), which we expect will be presented at ANA 2012 (Oct 7-9, Boston, MA) or ECTRIMS 2012 (Oct 10-13, Lyon, France); 2) the submission of regulatory filings for Soliris in the STEC-HUS indication (expected by YE'12 or early'13); and 3) Phase I results of ALXN 1102 (formerly TT30), a novel alternative pathway complement inhibitor in PNH."
FY12 EPS estimate raised from $1.79 to $1.87 and FY13 from $2.09 to $2.17.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $105.13 yesterday, with a 52 week range of $46.56-$105.32.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ying Huang calls Q2 earnings results an impressive beat and raise.
Looking forward Huang said, "Three potential catalysts on the horizon. We look forward to 1) the results of the Phase II investigator trial of Soliris in severe and refractory neuromyelitis optica (NMO), which we expect will be presented at ANA 2012 (Oct 7-9, Boston, MA) or ECTRIMS 2012 (Oct 10-13, Lyon, France); 2) the submission of regulatory filings for Soliris in the STEC-HUS indication (expected by YE'12 or early'13); and 3) Phase I results of ALXN 1102 (formerly TT30), a novel alternative pathway complement inhibitor in PNH."
FY12 EPS estimate raised from $1.79 to $1.87 and FY13 from $2.09 to $2.17.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $105.13 yesterday, with a 52 week range of $46.56-$105.32.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Goldman Sachs Downgrades Palo Alto Networks (PANW) to Buy
- Wells Fargo Upgrades ProLogis (PLD) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Barclays, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
